Pharmaceutical companies are appealing a High Court judgement that upheld the National Institute for Health and Clinical Excellence's decision to restrict the use of anti-dementia medicines for NHS patients in the early stages of Alzheimer's disease.
Eisai and Pfizer, which are launching the appeal, say it is based on the need for greater transparency from NICE about the cost-effectiveness model used for these treatments.
NHS England and Improvement are beginning the third and largest phase of the restructure bringing the two organisations together, which is expected in total to remove about 15 per cent of posts.
Sixty-three clinical commissioning groups have seen their overall performance ratings change over the past year, according to NHS England’s latest assessment framework.
Hospital trusts are continuing to allow patients to pay to have procedures which are banned or tightly restricted on the NHS, sparking a protest letter from NHS England.
We are aware that some of our users are experiencing problems accessing hsj.co.uk.
To protect your security as hsj.co.uk upgrades to a new platform, your existing password will no longer work.
Financial penalties are being lifted from high-profile standards including cancer and elective waiting times, so far without attracting much attention. How is this happening? And will it work, asks Rob Findlay
No comments yet